**Missed Opportunities for Stroke Prevention in Hypertensive Patients: A Retrospective Case-Control Study**

**Short title: Missed Opportunities for Stroke Prevention**

Huanhuan Yang, PhD; [1,2,3,#] Yuntian Liu, MPH; [1,4,#] Chungsoo Kim, PharmD, PhD; [1,3,5] Chenxi Huang, PhD; [1,3] Mitsuaki Sawano, MD, PhD; [1,3,6] Patrick Young, PhD; [3] Mark Anderson, AS; [7] John S. Burrows, MBA; [7] Harlan M. Krumholz, MD, SM; [1,3,8] John E. Brush, Jr., MD; [7,9,*] Yuan Lu, ScD [1,3,*]

[1] Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA

[2] Vanke School of Public Health, Tsinghua University, Beijing, China

[3] Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT, USA

[4] Department of Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, CT, USA

[5] Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea

[6] Teikyo Academic Research Center, Teikyo University, Tokyo, Japan

[7] Sentara Health, Norfolk, VA, USA

[8] Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut

[9] Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA, USA

[#]Contributed equally as Co-First Authors.

**[*]Corresponding authors:**

John E. Brush, Jr., MD, 800 Independence Blvd, Virginia Beach, VA, 23455

Phone: 757-477-1990, Email: jebrush@sentara.com.

&

Yuan Lu, ScD, 195 Church Street, Fifth Floor, New Haven, CT, 06510

Phone: 857-207-2460, Email: y.lu@yale.edu

**Total word count: 6729**

**Abstract**

**Background:** Hypertension is the leading modifiable risk factor for ischemic stroke, yet the

adequacy of preventative hypertension care in routine clinical practice remains suboptimal.

Whether gaps in hypertension management represent missed opportunities for stroke prevention

remains unclear.

**Objective:** To evaluate the association between hypertension care delivery and the risk of

incident ischemic stroke.

**Methods:** We conducted a retrospective, matched, nested case-control study among adults with

hypertension using electronic health record data from a large regional health system (2010–

2024). Patients with a first-ever ischemic stroke were matched 1:2 to controls on age, sex, race

and ethnicity, and calendar time. Three care metrics were assessed during follow-up: (1)

outpatient visits with blood pressure (BP) measurement per year; (2) number of antihypertensive

medication ingredients; and (3) medication intensification score. Conditional logistic regression

estimated adjusted odds ratios (aORs).

**Results:** The study included 13,476 cases and 26,952 matched controls (N = 40,428). Mean (SD)

age was 64.8 (12.2) years, 54.1% were female, and mean follow-up was 2,497 (1,308) days.

Cases had fewer BP visits per year (median, 2.50 vs. 3.01; p < 0.001), similar number of

medication ingredients (2.00 vs 2.00), and lower treatment intensification scores (-0.211 vs -

0.125). In adjusted models, >5 BP visits per year was associated with lower stroke odds (aOR,

0.55; 95% CI, 0.51-0.59) compared with ≤1 visit. Use of 2-3 medication ingredients (vs 0) was

also associated with reduced stroke odds (aOR, 0.80; 95% CI, 0.75-0.86), whereas >3 ingredients

was not significant. The highest quartile of treatment intensification showed the strongest

association (aOR, 0.47; 95% CI, 0.44-0.51).  Findings were consistent across subgroup and

sensitivity analyses, including strata defined by baseline SBP and follow-up SBP.

**Conclusions:** Greater engagement in hypertension care was associated with lower odds of

ischemic stroke, suggesting that gaps in routine management may represent missed opportunities

for prevention.

**Keywords:** Blood Pressure, Case-Control Study, Hypertension, Ischemic Stroke, Missed

Opportunities, Treatment Intensification

**Novelty and Relevance**

**What Is New?**

- In this nested case-control study, differences in hypertension care over time—including

follow-up frequency, medication use, and treatment adjustments—were associated with

incident ischemic stroke.

**What Is Relevant?**

- Variations in hypertension care delivery over time may represent missed opportunities for

stroke prevention regardless of baseline or average SBP levels during follow-up.

- Improving follow-up and timely treatment adjustments may offer actionable targets for

primary prevention.

**Clinical/Pathophysiological Implications**

- Longitudinal gaps in hypertension management may contribute to stroke risk beyond BP

control, highlighting opportunities to improve prevention through more consistent care

delivery.

**Introduction**

Each year in the United States, approximately 795,000 individuals experience a new or recurrent stroke, of which nearly 87% are ischemic strokes.[1] Stroke is the third major cause of death and long-term disability worldwide.[2] Importantly, elevated systolic blood pressure (SBP) accounts for more than one-half of the population-attributable risk for stroke.[2] Thus, lowering SBP is an important and highly effective strategy for reducing stroke risk.[3,4]

However, hypertension management in routine clinical practice remains suboptimal. National data indicate that fewer than half of US adults with hypertension achieve SBP <140/90 mm Hg, and fewer than one-quarter meet more stringent <130/80 mm Hg targets.[3,4] Achieving and maintaining BP control in practice requires sustained engagement with clinical care, including regular follow-up visits, appropriate medication use, and timely treatment intensification. These elements collectively reflect the delivery of hypertension care over time. However, it remains unclear whether differences in hypertension care delivery translate into meaningful differences in clinical outcomes.

Prior studies have described "therapeutic inertia", defined as the failure to initiate or intensify antihypertensive therapy when BP is uncontrolled, and have documented its high prevalence across diverse clinical settings.[5,6] However, most investigations of therapeutic inertia have focused on intermediate outcomes such as BP control rather than unambiguous cardiovascular endpoints such as ischemic stroke.[7] Furthermore, approaches to quantifying treatment intensification vary substantially across studies and may incompletely capture real-world therapeutic responsiveness to elevated BP.[8] More broadly, few studies have systematically

characterized longitudinal hypertension care patterns, including follow-up frequency,

antihypertensive medication exposure, and treatment intensification, as a unified care delivery

construct in relation to stroke risk in routine practice. In addition, differences in observation

windows or follow-up duration between comparison groups in observational studies may

complicate interpretation of the temporal relationship between management gaps and subsequent

stroke events.

To address these gaps, we leveraged longitudinal electronic health record (EHR) data

standardized to the Observational Medical Outcomes Partnership (OMOP) common data model

to examine patterns of hypertension care preceding stroke. Using a time-aligned matched case-

control design to ensure comparable observation windows, we quantified the association between

hypertension care delivery and the risk of incident ischemic stroke. By linking real-world

patterns of BP management to stroke outcomes, this study aims to identify potentially modifiable

gaps in hypertension care that may represent missed opportunities for stroke prevention.

**Methods**

**Data Source**

This retrospective case-control study was conducted using EHR data from Sentara Health, a

large nonprofit integrated regional healthcare system serving Virginia and northeastern North

Carolina, comprising 12 hospitals, 500+ outpatient care sites, and affiliated medical groups. All

EHR data were standardized to the OMOP common data model. The study period spanned from

January 1, 2010, to December 31, 2024.

**Study Population**

The study population was derived from 3,728,562 patients with at least one documented

encounter during the study period (Supplemental Figure 1). To ensure adequate longitudinal

observation, we restricted the cohort to patients with documented encounters over at least 5 years,

defined as the interval between the first and last recorded encounter (n = 1,390,427 patients). To

ensure adequate frequency of observations, we then restricted the cohort to patients with a rate of

years with visits (RYV) ≥0.5. RYV was calculated as the number of calendar years with at least

one documented encounter divided by the total calendar years of the observation period. Among

the remaining patients (n = 1,027,277), we identified 546,120 individuals with hypertension,

forming the hypertensive cohort.  The definition of hypertension is provided below.

**Study Design**

We conducted a retrospective 1:2 matched nested case-control study within the hypertensive

cohort (Figure 1). The index date (T□ for cases and T□′ for controls) was defined as the date

when patients first met the definition of hypertension. Cases were defined as patients with an

incident ischemic stroke occurring more than 60 days after T□. A 60-day blanking period was

applied to reduce potential reverse causation and to allow sufficient time for exposure assessment.

Care processes occurring within 60 days after the index date were excluded, as healthcare

encounters shortly after hypertension diagnosis may reflect diagnostic evaluation or early clinical

management rather than stable patterns of routine hypertension care.[9] The stroke admission date

was defined as T□. For each case, the duration between T□ and T□ (ΔT) was calculated.

Controls were selected from patients in the hypertensive cohort who remained free of stroke

during the corresponding follow-up interval.

**Matching Strategy and Temporal Alignment**

Each case was matched with two controls (1:2 matching) on age, sex, and race/ethnicity at ~~T□~~

the index date. To ensure temporal comparability, controls were additionally required to have

index date (T□′) within ±30 days of the corresponding case's T□. Among eligible controls, those

with the smallest absolute difference in index date were preferentially selected. Each control

patient was selected only once. To align follow-up duration between cases and controls, we

implemented a time-aligned matching approach. For each matched control, a pseudo-event date

(T□′) was generated by adding the case-specific ΔT to the control patient's index date (T□′).

This ensured identical observation windows (T□ to T□ for cases; T□′ to T□′ for controls). To

minimize bias due to differential follow-up or informative loss to care, controls were required to

have at least one clinical encounter within ±30 days of T□, indicating ongoing engagement in

care at the comparable time point.

After matching and temporal alignment, matched sets without outpatient visits with recorded BP

measurements during the observation window were excluded. The final analytic cohort included

a total of 40,428 participants (13,476 cases and 26,952 controls).

**Definition of Hypertension**

Hypertension was defined by the presence of any one of the following: (1) a coded diagnosis of

hypertension (Supplemental Table 1); (2) a recorded prescription for one or more

antihypertensive medications (Supplemental Table 2); or (3) at least two outpatient visits with

elevated BP (either SBP ≥140 or diastolic BP [DBP] ≥90 mmHg). The 140/90 mmHg threshold

was used to identify clearly elevated BP consistent with clinical practice and hypertension

definitions widely used during most of the study period (2010–2024). If multiple BP

measurements were recorded during a visit, the first reading was discarded, and the mean of the

remaining measurements was calculated.[10] If multiple outpatient visits occurred on the same day,

the average BP across visits was calculated.

**Definition of Ischemic Stroke**

Ischemic stroke was defined as an incident ischemic cerebrovascular event identified using

validated OMOP concept sets (Supplemental Table 1). Patients with hemorrhagic stroke were

excluded. If ischemic stroke and hemorrhagic stroke were both recorded on the same day, the

event was classified as an ischemic stroke.

**Definition of Hypertension Care Delivery**

Hypertension care delivery during the observation window ($T_\square$ to $T_\square$ for cases and $T_\square'$ to $T_\square'$

for controls) was quantified using three complementary measures: number of outpatient visits

with BP measurement per year; number of antihypertensive medication ingredients;

antihypertensive medication intensification score.

The antihypertensive medication intensification score was calculated as:[11]

$$\frac{(Number\ of\ outpatient\ visits\ with\ medication\ intensification) - (Number\ of\ outpatient\ visits}{Total\ number\ of\ outpatient\ visits\ with\ BP\ measurement}$$

The score ranges from -1.0 to 1.0. Higher values reflect greater therapeutic responsiveness

relative to episodes of uncontrolled BP, whereas lower values indicate a higher burden of

elevated BP relative to medication intensification. Elevated BP used for defining treatment

intensification was based on a threshold of SBP ≥140 mmHg or DBP ≥90 mmHg. This threshold

was selected to identify episodes of clearly uncontrolled hypertension where treatment escalation

would typically be expected in routine clinical practice.

Medication intensification was defined as 1) initiation of antihypertensive therapy (transition

from untreated to treated), 2) addition of a new antihypertensive medication ingredient, or 3) an

increase in ingredient-level daily dose compared with the prior visit. All intensification events

occurring within the observation window were counted, regardless of whether elevated BP was

documented at the same visit.

**Covariates**

Baseline covariates assessed at T☐ included age, sex, race and ethnicity, area-level social

vulnerability index (SVI) based on the patient's recorded address at baseline, baseline SBP and

DBP, and comorbid conditions identified prior to T☐, including congestive heart failure (CHF),

chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), atrial fibrillation

(AF), diabetes, and dementia (Supplemental Table 1)

**Statistical Analysis**

Baseline characteristics were summarized using means (SD) or median (interquartile range, IQR)

for continuous variables, and frequencies (%) for categorical variables. Group differences were

assessed using Welch's two-sample t-tests or Wilcoxon rank-sum tests for continuous variables

and Pearson's chi-square tests for categorical variables, as appropriate. Given the matched nested

case-control design with temporally aligned observation windows, associations between

hypertension care delivery measures and incident ischemic stroke were estimated using

conditional logistic regression to account for the matched design.[12] Three models were

constructed: Model 0 was unadjusted; Model 1 was adjusted for baseline SBP; Model 2 was

further adjusted for SVI, CHF, CKD, COPD, AF, diabetes, and dementia. Care delivery measures

were modeled as categorical variables according to pre-specified groupings: outpatient visits

with BP measurement per year ($\leq 1$, 2-3, 4-5, >5 visits), number of antihypertensive medication

ingredients (0, 1, 2-3, >3), and treatment intensification score (quartiles). Categorization was

chosen to facilitate clinical interpretability. Pre-specified subgroup analyses were conducted

stratified by baseline SBP, average SBP during the observation window (<130 vs $\geq$130 mmHg),

sex, age group, race/ethnicity, and SVI (quartile). Interaction terms were tested to evaluate effect

modification. In sensitivity analyses, a more stringent threshold (BP $\geq$160/100 mmHg) was

applied. Additional analyses were conducted after excluding matched sets in which any patient

had baseline cardiometabolic comorbidities (CHF, AF, or CKD), and in a separate analysis after

excluding matched sets with any baseline comorbidity (CHF, AF, or CKD, COPD, diabetes, or

dementia). Missing data were handled through study design. Participants with missing key

variables were excluded during cohort construction and matching.

All statistical tests were two-sided, with P <0.05 considered statistically significant. Data

extraction from the OMOP common data model was performed using Microsoft SQL Server, and

statistical analyses were conducted using R version 4.2.3 (R Foundation for Statistical

Computing).

The study protocol was approved by the Institutional Review Board of the Malcolm and Joan

Brock Virginia Health Sciences at Old Dominion University, which granted a waiver of informed

consent and authorization due to the retrospective design. The study was conducted in

accordance with STROBE guidelines.

**Results**

Basic characteristics were shown in Table 1**.** Age, sex, race and ethnicity, and follow-up duration

(mean [SD], 2,497.4 [1,307.6] days) were well balanced between cases and controls. Mean (SD)

age at index was 64.8 (12.2) years, and 54.1% were women. The cohort was predominantly non-

Hispanic White (64.9%) and non-Hispanic Black (33.8%). Distribution of the SVI differed

between cases and controls (p < 0.001), with cases slightly more likely to reside in more

vulnerable areas. Baseline SBP and DBP were higher among cases compared with controls (SBP,

135.7 vs. 132.1 mm Hg; DBP, 77.0 vs. 76.5 mm Hg; both p < 0.001). Average follow-up BP

values were also higher in cases (SBP, 135.5 vs. 131.6 mm Hg; DBP, 76.2 vs. 75.4 mm Hg; both

p < 0.001). Prevalence of several comorbidities, including CHF, CKD, COPD, AF, diabetes, and

dementia, was also higher among cases (all p < 0.001).

During the matched observation window, cases had fewer outpatient visits with BP measurement

per year than controls (median, 2.50 vs. 3.01; p < 0.001). Total number of antihypertensive

medication ingredients had the same median in the two groups (median [IQR], 2.00 [1.00-4.00]

in both groups). The intensification score defined using the 140/90 threshold was lower among

cases than controls (median [IQR], -0.211 [-0.455, 0] vs. -0.125 [-0.333, 0]; p < 0.001),

indicating a higher burden of elevated BP relative to medication intensification. Similar patterns

were observed when the 160/100 threshold was used (median [IQR], 0 [0, 0.139] vs. 0 [0, 0.167];

p < 0.001). Distributions of the three hypertension care delivery measures are shown in

Supplemental Figure 2.

**Association Between Hypertension Care Delivery and Ischemic Stroke Risk**

In conditional logistic regression analyses, greater engagement in hypertension care delivery was

generally associated with lower odds of ischemic stroke (Table 2).

For outpatient visits with BP measurement, increasing visit frequency up to 4-5 visits per year

was associated with progressively lower odds of ischemic stroke. Compared with ≤1 visit per

year, the adjusted odds ratios (aORs) in Model 2 were 0.52 (95% CI, 0.49-0.55) for 2-3 visits and

0.43 (95% CI, 0.40-0.46) for 4-5 visits. However, the association was attenuated among

individuals with more than 5 visits per year (aOR, 0.55; 95% CI, 0.51-0.59), which may reflect

greater underlying disease severity or higher healthcare utilization among patients requiring

more frequent visits.

A similar pattern was observed for the number of antihypertensive medication ingredients.

Compared with no antihypertensive medication use, the odds of stroke were lower among

patients receiving one medication ingredient (aOR, 0.83; 95% CI, 0.78-0.90) and those receiving

2-3 ingredients (aOR, 0.80; 95% CI, 0.75-0.86). In contrast, use of more than three medication

ingredients was not associated with lower stroke risk in fully adjusted models (aOR, 1.03; 95%

CI, 0.96-1.10).

Higher treatment intensification scores were consistently associated with lower odds of ischemic

stroke in a graded fashion. Compared with quartile 1, aORs in Model 2 were 0.68 (95% CI, 0.64-

0.72) for quartile 2, 0.62 (95% CI, 0.58-0.65) for quartile 3, and 0.47 (95% CI, 0.44-0.51) for

quartile 4. Results were similar in sensitivity analyses using a more stringent definition of

elevated BP ($\geq$160/100 mm Hg) (Supplemental Table 3).

**Subgroup Analyses by Baseline and Average SBP**

Associations between hypertension care metrics and ischemic stroke were broadly consistent

across strata of both baseline SBP and average SBP during the observation window (Figures 2

and 3). For outpatient visit frequency, more frequent visits were associated with lower odds of

ischemic stroke across SBP strata, with no significant interaction by baseline SBP (p for

interaction = 0.06) or average SBP (p for interaction = 0.38).

For the number of antihypertensive medication ingredients, the overall pattern of association

with ischemic stroke was generally similar across strata of both baseline and average SBP.

Although the interaction with baseline SBP reached statistical significance (p for interaction =

0.025), the direction of association was broadly consistent across SBP strata. In contrast, no

interaction was observed by average SBP (p for interaction = 0.96).

For treatment intensification score, higher scores were associated with lower odds of ischemic

stroke across SBP strata. However, both baseline SBP (p for interaction = 0.008) and average

SBP (p for interaction = 0.041) showed modest effect modification, with somewhat stronger

associations observed among individuals with higher SBP.

**Subgroup Analyses by Sex, Age, Race/Ethnicity, and SVI**

Associations were similar between women and men (Supplemental Table 4). Compared with ≤1 outpatient BP visit per year, having 4-5 visits per year was associated with lower odds of ischemic stroke in both women (aOR 0.47, 95% CI 0.43-0.52) and men (aOR 0.38, 95% CI 0.35-0.42), with no evidence of interaction by sex (p for interaction = 0.13). Similarly, the associations for the number of antihypertensive medication ingredients and treatment intensification score did not differ significantly between sexes (p for interaction = 0.27 and 0.73, respectively).

In contrast, associations differed across age groups (Supplemental Table 5). The relationship between the number of antihypertensive medication ingredients and ischemic stroke risk varied significantly by age (p for interaction <0.001). In particular, use of >3 medication ingredients was associated with higher odds of ischemic stroke among individuals aged <45 years (aOR 1.74, 95% CI 1.29-2.36), whereas no clear association was observed among those aged ≥60 years (aOR 0.96, 95% CI 0.88-1.04). Effect modification by age was also observed for treatment intensification score (p for interaction <0.001).

Associations also varied by race and ethnicity (Supplemental Tables 6-1 and 6-2). Among non-Hispanic White and non-Hispanic Black patients, greater outpatient BP visit frequency and higher treatment intensification scores were associated with lower odds of ischemic stroke. However, estimates among Hispanic/Latino, non-Hispanic Asian, and other racial groups were less precise, likely reflecting smaller sample sizes. Significant interaction by race/ethnicity was observed for outpatient BP visit frequency and treatment intensification score (both p for

interaction <0.001), whereas the association for medication ingredients counts did not differ

significantly across racial and ethnic groups (p for interaction = 0.18).

Associations also varied across levels of social vulnerability (Supplemental Table 7). The

association between outpatient BP visit frequency and ischemic stroke differed by SVI quartile

(p for interaction = 0.011), with lower stroke odds associated with more frequent BP visits in

lower SVI quartiles but a weaker association in the highest SVI quartile. Similarly, the

relationship between the number of antihypertensive medication ingredients and ischemic stroke

risk varied across SVI strata (p for interaction = 0.013). In contrast, the association between

antihypertensive treatment intensification score and ischemic stroke risk was generally consistent

across SVI quartiles (p for interaction = 0.18).

**Sensitivity Analyses**

Sensitivity analyses excluding matched sets with baseline cardiometabolic conditions (CHF, AF,

or CKD) yielded results similar to the primary analysis (Supplemental Table 8). In a more

restrictive analysis excluding matched sets in which any patient had major baseline comorbidities

(CHF, AF, CKD, COPD, diabetes, or dementia), the associations between outpatient BP visit

frequency, antihypertensive medication ingredients, treatment intensification score, and ischemic

stroke remained largely unchanged.

**Discussion**

In this large, real-world, matched, case-control study of adults with hypertension, we identified

patterns of outpatient hypertension care that were associated with incident ischemic stroke.

Using complementary measures of BP monitoring frequency, antihypertensive medication use,

and a treatment intensification score reflecting clinical responsiveness to elevated BP, we found

that greater engagement in hypertension care was generally associated with lower odds of stroke.

Specifically, more frequent outpatient BP visits and use of 1 to 3 antihypertensive medication

ingredients were associated with lower stroke odds, and higher treatment intensification scores

showed a graded inverse association with stroke risk. Importantly, these associations were

observed across strata of both baseline SBP and average SBP during follow-up, suggesting that

care delivery patterns capture aspects of hypertension management beyond BP level alone. These

findings indicate that missed opportunities for ischemic stroke prevention may exist within

routine hypertension care delivery.

Patterns of routine outpatient hypertension care appeared to play an important role in stroke risk.

Patients with more frequent BP-related visits, particularly those with up to four to five visits per

year, experienced substantially lower odds of ischemic stroke compared with individuals with

minimal monitoring. Regular BP measurement may facilitate earlier detection of uncontrolled

hypertension, timely treatment adjustments, and reinforcement of adherence to therapy and

lifestyle modification.[13] At the same time, the association between visit frequency and stroke risk

did not show a consistent stepwise pattern across categories. Individuals with very frequent visits

(>5 per year) did not demonstrate further reductions in stroke risk relative to those with four to

five visits annually. This pattern likely reflects the complex relationship between care utilization

and underlying disease severity. Patients requiring very frequent visits may represent a subgroup

with more unstable BP, treatment-resistant hypertension, or greater comorbidity burden, factors

that may partially offset the benefits of closer monitoring.[14,15]

The number of antihypertensive medication ingredients was also associated with stroke risk.

Compared with patients receiving no antihypertensive medications, those treated with one or two

to three medication ingredients had significantly lower odds of ischemic stroke, consistent with

the established benefit of pharmacologic BP control in reducing cardiovascular risk.[16] However,

the use of more than three medication ingredients was not associated with additional reductions

in stroke risk in fully adjusted models. This finding should be interpreted cautiously, as the

number of prescribed medications may reflect both treatment intensity and underlying disease

complexity.[16] Patients receiving multiple antihypertensive agents often have more severe or

treatment-resistant hypertension and may also have higher baseline cardiovascular risk.[17] In this

context, medication ingredient counts may simultaneously represent both intensified treatment

and greater disease burden.

In contrast to the more heterogeneous patterns observed for visit frequency and medication

ingredients counts, the treatment intensification score demonstrated a clear graded association

with stroke risk. Higher intensification scores reflecting greater clinical responsiveness to

elevated BP were consistently associated with lower odds of ischemic stroke. These findings are

consistent with the concept of therapeutic inertia, defined as the failure to initiate or intensify

antihypertensive therapy in the setting of uncontrolled BP.[18] Prior studies have documented the

widespread prevalence of therapeutic inertia across clinical settings and have linked it to poorer

intermediate outcomes, particularly inadequate BP control.[6,19-21] Our results extend this literature

by demonstrating that patterns of treatment intensification over time may also be associated with

differences in hard cardiovascular outcomes, including incident ischemic stroke.

Our findings are consistent with prior studies highlighting the importance of care processes in

hypertension management. For example, Fontil et al. demonstrated that differences in treatment

intensification and visit adherence were strongly associated with blood pressure control.[11] In

addition, large cohort and registry studies have shown that delays in medication intensification

and prolonged intervals to follow-up after elevated BP are associated with increased risks of

cardiovascular events or death, and lower treatment intensification scores are linked to higher

risks of recurrent stroke.[22] Building on this prior work, our study sought to characterize

longitudinal patterns of hypertension care delivery across several complementary dimensions. In

doing so, we demonstrate that care delivery patterns capture aspects of hypertension

management beyond BP level alone.

Subgroup analyses provided additional insight into how these care delivery patterns may operate

across patient populations. The association between outpatient BP monitoring frequency and

stroke risk was broadly similar across both baseline SBP and average SBP during the observation

window, suggesting that regular monitoring may confer benefits regardless of whether baseline

BP is moderately elevated or more substantially elevated. In contrast, the relationships between

medication ingredients counts and treatment intensification with stroke risk varied across certain

demographic subgroups, including age and race or ethnicity. These differences may reflect

variations in underlying hypertension severity, treatment response, comorbidity patterns, or

healthcare access across populations. Importantly, however, the general direction of association

for treatment intensification remained consistent across subgroups, reinforcing the importance of

active clinical responsiveness to uncontrolled BP.

Taken together, these findings underscore the potential role of routine outpatient hypertension

care processes in shaping long-term cardiovascular outcomes. Hypertension management in

clinical practice often occurs through a series of outpatient encounters in which BP is measured,

medications are adjusted, and adherence and lifestyle behaviors are discussed. Missed

opportunities within these encounters, whether through infrequent monitoring, insufficient

medication escalation, or delayed treatment intensification, may accumulate over time and

contribute to the development of preventable cardiovascular events.[14,23,24] From a

pathophysiological perspective, chronic exposure to elevated BP contributes to endothelial

dysfunction, arterial stiffening, and small-vessel disease, all of which increase susceptibility to

ischemic stroke.[25-28] These results suggest that improving the quality and responsiveness of

routine hypertension care delivery may represent an important avenue for stroke prevention.

Several practical strategies may help improve hypertension management in routine clinical

practice, including structured follow-up programs to ensure regular BP monitoring, standardized

protocols for BP measurement and treatment escalation, and the use of EHR-based clinical

decision support tools to prompt timely medication adjustments. In addition, team-based care

models involving pharmacists, nurses, and care coordinators may support medication

management, patient education, and adherence, thereby improving long-term BP control.

This study has several strengths. First, it leveraged a large longitudinal EHR cohort within an

integrated health system, enabling comprehensive capture of outpatient visits, BP measurements,

and medication prescribing over extended follow-up. The integrated structure of the Sentara

Health system, which includes hospitals, outpatient practices, and affiliated medical groups

within a shared EHR environment, facilitates more complete longitudinal capture of routine

hypertension care processes. Second, the matched case-control design enabled careful alignment

of observation windows between cases and controls, reducing potential bias arising from

differences in follow-up time. Third, we evaluated multiple complementary measures of

hypertension care delivery, capturing different dimensions of outpatient management including

monitoring, medication use, and treatment responsiveness. Together, these measures provide a

more comprehensive representation of longitudinal hypertension care patterns than single cross-

sectional metrics.

Several limitations should also be considered. First, this study was conducted within a single

integrated regional health system. Although the large sample size and long observation period

enhance the robustness of the findings, healthcare delivery models, insurance structures, and

patient populations may differ across health systems and geographic regions. Although this

regional health system is typical, the generalizability of these findings to other healthcare

environments should be interpreted carefully. Second, as with all observational studies, residual

confounding cannot be completely excluded, and the associations observed do not establish

causality. Third, medication prescribing patterns were assessed using prescription records rather

than measures of medication adherence, and actual medication use may therefore differ from

recorded prescriptions. Fourth, care delivered outside the participating healthcare system may

not have been captured, potentially leading to incomplete measurement of outpatient visits,

medication exposure, or outcomes. Finally, the number of medication ingredients prescribed may

reflect both treatment intensity and underlying disease severity, making interpretation of these

associations complex.

437 In conclusion, longitudinal patterns of outpatient hypertension care delivery, including BP

438 monitoring frequency, antihypertensive medication use, and treatment intensification, were

439 associated with the risk of incident ischemic stroke in this large real-world cohort. These findings

440 suggest that opportunities for stroke prevention may exist within routine outpatient hypertension

441 care processes. Efforts to improve the consistency and responsiveness of hypertension

442 management in everyday clinical practice—such as structured follow-up programs, standardized

443 BP monitoring protocols, and timely treatment intensification supported by EHR-based decision

444 support—may represent an important strategy for reducing the burden of stroke.

**Data Availability**

Due to patient privacy considerations, the data underlying this study are housed within a secure

environment maintained by Sentara Health and are not publicly available. However, limited

deidentified data and additional details regarding the analytic methods may be made available by

the corresponding author (J.B.) upon reasonable request.

**Acknowledgment**

We gratefully acknowledge Dr. Valy Fontil for his expert guidance on the methodology for

calculating the medication treatment intensification score. We also thank Dr. Jacob McPadden for

his helpful input during the early stages of this study.

**Sources of Funding**

This research was funded in part by the Batten Foundation, Norfolk, VA, and the Hampton

Roads Biomedical Research Consortium, Portsmouth, VA. Dr Brush receives support from the

Patient-Centered Outcomes Research Institute (under award HN-2022C202854).

**Author Contributions**

Y. Liu and J. Brush had full access to all of the study data and took full responsibility for the

integrity and accuracy of the analysis. H. Yang, H. Krumholz, J. Brush, and Y. Lu are responsible

for the conceptualization of the study. C. Kim, C. Huang, and M. Sawano contributed to the

study design. P. Young, and M. Anderson contributed to the study analysis. H. Yang wrote the

first draft, with contributions from all other authors. All authors reviewed and approved the final

article.

**Disclosures**

In the last 3 years, Dr. Sawano has been partially supported by research funding from Polybio,

Pfizer, and Novartis through Yale University; he has also received lecture honoraria from

Boehringer Ingelheim and Abbott. Dr. Young and McPadden are consultants for Refactor Health,

Inc., which provides data processing services to Sentara Health. In the past 3 years, Dr.

Krumholz has received options for Element Science and Identifeye and payments from F-Prime

for advisory roles; is a co-founder of and holds equity in Hugo Health, Refactor Health, and

ENSIGHT-AI; and is associated with research contracts through Yale University from Janssen,

Kenvue, Novartis, and Pfizer. Dr. Lu receives support from the National Heart, Lung, and Blood

Institute of the National Institutes of Health (under awards R01HL69954 and R01HL169171),

the Patient-Centered Outcomes Research Institute (under award HM-2022C2-28354), Sentara

Research Foundation, and Novartis through Yale University. All other authors have reported that

they have no relationships relevant to the contents of this paper to disclose.

**Nonstandard abbreviations and acronyms**

**AF** Atrial fibrillation

**CHF** Congestive heart failure

**CKD** Chronic kidney disease

**COPD** Chronic obstructive pulmonary disease

**DBP** Diastolic blood pressure

**EHR** Electronic health record

**HTN** Hypertension

**OMOP** Observational Medical Outcomes Partnership

**OP** Outpatient

**aOR** Adjusted odds ratio

**RYV** Rate of years with visits

**SBP** Systolic blood pressure

**SVI** Social vulnerability index

**References**

1.    Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023

Update: A Report From the American Heart Association. *Circulation*. 2023;147(8):e93-e621.

2.    Feigin VL, Abate MD, Abate YH, et al. Global, regional, and national burden of stroke

and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease

Study 2021. *The Lancet Neurology*. 2024;23(10):973-1003.

3.    Muntner P, Hardy ST, Fine LJ, et al. Trends in Blood Pressure Control Among US Adults

With Hypertension, 1999-2000 to 2017-2018. *Jama*. 2020;324(12):1190-1200.

4.    Hypertension Cascade: Hypertension Prevalence, Treatment and Control Estimates

Among US Adults Aged 18 Years and Older Applying the Criteria From the American College of

Cardiology and American Heart Association's 2017 Hypertension Guideline—NHANES 2017–

2020. Centers for Disease Control and Prevention (CDC). May 12, 2023. Accessed (specify date

accessed). https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html.

5.    Dixon Dave L, Sharma G, Sandesara Pratik B, et al. Therapeutic Inertia in

Cardiovascular Disease Prevention. *JACC*. 2019;74(13):1728-1731.

6.    Darricarrere C, Jacquot E, Bricout S, et al. Uncontrolled blood pressure and therapeutic

inertia in treated hypertensive patients: A retrospective cohort study using a UK general practice

database. *J Clin Hypertens (Greenwich)*. 2023;25(10):895-904.

7.    Mohl JT, Moreno CA, Sadik K, et al. Evaluation of Blood Pressure Control, Medication

Adherence, and Therapeutic Inertia in US Patients With Hypertension Prescribed Multiple

Antihypertensives. *Journal of the American Heart Association*. 2025;14(12):e034787.

8.        Rose AJ, Berlowitz DR, Manze M, Orner MB, Kressin NR. Comparing methods of

measuring treatment intensification in hypertension care. *Circ Cardiovasc Qual Outcomes*.

2009;2(4):385-91.

9.        Arfè A, Corrao G. The lag-time approach improved drug-outcome association estimates

in presence of protopathic bias. *J Clin Epidemiol*. 2016;78:101-107.

10.      Muntner P, Shimbo D, Carey RM, et al. Measurement of Blood Pressure in Humans: A

Scientific Statement From the American Heart Association. *Hypertension*. 2019;73(5):e35-e66.

11.      Fontil V, Pacca L, Bellows BK, et al. Association of Differences in Treatment

Intensification, Missed Visits, and Scheduled Follow-up Interval With Racial or Ethnic

Disparities in Blood Pressure Control. *JAMA Cardiol*. 2022;7(2):204-212.

12.      Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of

case-control studies. *IARC Sci Publ*. 1980;(32):5-338.

13.      Abdalla M, Bolen SD, Brettler J, et al. Implementation Strategies to Improve Blood

Pressure Control in the United States: A Scientific Statement From the American Heart

Association and American Medical Association. *Hypertension*. 2023;80(10):e143-e157.

14.      Kim D, Jeong H, Kim S, et al. Association between office visit intervals and long-term

cardiovascular risk in hypertensive patients. *J Clin Hypertens (Greenwich)*. 2023;25(8):748-756.

15.      Carey RM, Moran AE, Whelton PK. Treatment of Hypertension: A Review. *JAMA*.

2022;328(18):1849-1861.

16.      Wei J, Galaviz KI, Kowalski AJ, et al. Comparison of Cardiovascular Events Among

Users of Different Classes of Antihypertension Medications: A Systematic Review and Network

Meta-analysis. *JAMA Network Open*. 2020;3(2):e1921618-e1921618.

17.      Pharmacological blood pressure lowering for primary and secondary prevention of

cardiovascular disease across different levels of blood pressure: an individual participant-level

data meta-analysis. *Lancet*. 2021;397(10285):1625-1636.

18.      Rea F, Corrao G, Merlino L, Mancia G. Initial Antihypertensive Treatment Strategies and

Therapeutic Inertia. *Hypertension*. 2018;72(4):846-853.

19.      Ali DH, Kiliç B, Hart HE, et al. Therapeutic inertia in the management of hypertension in

primary care. *J Hypertens*. 2021;39(6):1238-1245.

20.      Zheutlin AR, Mondesir FL, Derington CG, et al. Analysis of Therapeutic Inertia and Race

and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a

Randomized Clinical Trial. *JAMA Network Open*. 2022;5(1):e2143001-e2143001.

21.      Mohl JT, Moreno CA, Sadik K, et al. Evaluation of Blood Pressure Control, Medication

Adherence, and Therapeutic Inertia in US Patients With Hypertension Prescribed Multiple

Antihypertensives. *J Am Heart Assoc*. 2025;14(12):e034787.

22.      Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time

to intensification, and time to follow-up in treatment of hypertension: population based

retrospective cohort study. *Bmj*. 2015;350:h158.

23.      Lu Y, Brush JE, Jr., Kim C, et al. Delayed Hypertension Diagnosis and Its Association

With Cardiovascular Treatment and Outcomes. *JAMA Network Open*. 2025;8(7):e2520498-

e2520498.

24.      Howard G, Muntner P, Lackland DT, et al. Association of Duration of Recognized

Hypertension and Stroke Risk: The REGARDS Study. *Stroke*. 2025;56(1):105-112.

25.      Lerman LO, Kurtz TW, Touyz RM, et al. Animal Models of Hypertension: A Scientific

Statement From the American Heart Association. *Hypertension*. 2019;73(6):e87-e120.

26.    Petrea RE, O'Donnell A, Beiser AS, et al. Mid to Late Life Hypertension Trends and

Cerebral Small Vessel Disease in the Framingham Heart Study. *Hypertension*. 2020;76(3):707-

714.

27.    Lau KK, Li L, Simoni M, et al. Long-Term Premorbid Blood Pressure and Cerebral

Small Vessel Disease Burden on Imaging in Transient Ischemic Attack and Ischemic Stroke.

*Stroke*. 2018;49(9):2053-2060.

28.    Webb AJS, Werring DJ. New Insights Into Cerebrovascular Pathophysiology and

Hypertension. *Stroke*. 2022;53(4):1054-1064.

**Table 1. Baseline Characteristics of Participants in Case and Control Groups (1:2).**

| Characteristic | Overall<br>N = 40,428 | Case Group<br>N = 13,476 | Control Group<br>N = 26,952 | p-value |
|---|---|---|---|---|
| **Age at $T_0$** [a] | 64.8 (12.2) | 64.8 (12.2) | 64.8 (12.2) | >0.90 |
| **Sex** | | | | >0.90 |
| Female | 21,852 (54.1%) | 7,284 (54.1%) | 14,568 (54.1%) | |
| Male | 18,576 (45.9%) | 6,192 (45.9%) | 12,384 (45.9%) | |
| **Race & Ethnicity** | | | | >0.90 |
| Hispanic/Latino | 162 (0.4%) | 54 (0.4%) | 108 (0.4%) | |
| Non-Hispanic Asian | 237 (0.6%) | 79 (0.6%) | 158 (0.6%) | |
| Non-Hispanic Black | 13,680 (33.8%) | 4,560 (33.8%) | 9,120 (33.8%) | |
| Non-Hispanic White | 26,223 (64.9%) | 8,741 (64.9%) | 17,482 (64.9%) | |
| Other/Unknown | 126 (0.3%) | 42 (0.3%) | 84 (0.3%) | |
| **SVI** | | | | <0.001 |
| Quartile 1 | 9,934 (24.6%) | 3,092 (22.9%) | 6,842 (25.4%) | |
| Quartile 2 | 9,439 (23.3%) | 3,204 (23.8%) | 6,235 (23.1%) | |
| Quartile 3 | 7,216 (17.8%) | 2,642 (19.6%) | 4,574 (17.0%) | |
| Quartile 4 | 4,239 (10.5%) | 1,583 (11.7%) | 2,656 (9.9%) | |
| **Days $T_0$-$T_1$** [b] | 2,497 (1,307.6) | 2,497 (1,307.6) | 2,497 (1,307.7) | >0.90 |
| **Blood Pressure Metrics** | | | | |
| Baseline Systolic BP | 133.3 (18.1) | 135.7 (19.8) | 132.1 (17.1) | <0.001 |
| Baseline Diastolic BP | 76.6 (11.4) | 77.0 (12.2) | 76.5 (10.9) | <0.001 |
| Average Systolic BP | 132.9 (12.3) | 135.5 (13.9) | 131.6 (11.1) | <0.001 |
| Average Diastolic BP | 75.7 (8.0) | 76.2 (9.1) | 75.4 (7.4) | <0.001 |
| **Comorbid Conditions** | | | | |
| CHF | 458 (1.1%) | 211 (1.6%) | 247 (0.9%) | <0.001 |
| CKD | 1,453 (3.6%) | 635 (4.7%) | 818 (3.0%) | <0.001 |
| COPD | 2,406 (6.0%) | 986 (7.3%) | 1,420 (5.3%) | <0.001 |
| AF | 2,141 (5.3%) | 804 (6.0%) | 1,337 (5.0%) | <0.001 |
| Diabetes | 10,519 (26.0%) | 4,388 (32.6%) | 6,131 (22.7%) | <0.001 |
| Dementia | 344 (0.9%) | 161 (1.2%) | 183 (0.7%) | <0.001 |
| **Number of OP visits with BP per year** [c] | 2.88 (1.43, 4.66) | 2.50 (0.99, 4.65) | 3.01 (1.67, 4.67) | <0.001 |
| **Number of anti-HTN medication ingredients** [c] | 2.00 (1.00, 4.00) | 2.00 (1.00, 4.00) | 2.00 (1.00, 4.00) | <0.001 |
| **Drug intensification score (140/90)** [c] | -0.150 (-0.364, 0) | -0.211 (-0.455, 0) | -0.125 (-0.333, 0) | <0.001 |
| **Drug intensification score (160/100)** [c] | 0.053 (0, 0.160) | 0 (0, 0.139) | 0.069 (0, 0.167) | <0.001 |

[a] $T_0$ indicates the date of hypertension diagnosis; [b] $T_1$ indicates the date of first stroke
admission or the matched outpatient visit for controls.

[c] Exposure variables are presented as median (interquartile range [IQR]) and compared using the
Wilcoxon rank-sum test. Other continuous variables are presented as mean (SD) and compared
using Welch's two-sample t-test; categorical variables are expressed as n (%) and compared using
the Pearson chi-square test.
Abbreviations: AF, atrial fibrillation; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; CHF, congestive heart failure; CKD, chronic kidney disease; HTN, hypertension; IQR,
interquartile range; OP, outpatient visits; SVI, social vulnerability index.

**Table 2. Conditional logistic regression of hypertension care delivery measures and stroke**
**incidence**.

| | Unadjusted Model [a] | | Adjusted Model 1 [b] | | Adjusted Model 2 [c] | |
|---|---|---|---|---|---|---|
| | ORs (95% CI) | P-value | aORs (95% CI) | p-value | aORs (95% CI) | p-value |
| **Number of OP visits with BP per year** | | | | | | |
| ≤1 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| 2-3 | 0.50 (0.47-0.53) | <0.001 | 0.51 (0.48-0.54) | <0.001 | 0.52 (0.49-0.55) | <0.001 |
| 4-5 | 0.41 (0.39-0.44) | <0.001 | 0.43 (0.40-0.46) | <0.001 | 0.43 (0.40-0.46) | <0.001 |
| >5 | 0.56 (0.52-0.60) | <0.001 | 0.58 (0.54-0.62) | <0.001 | 0.55 (0.51-0.59) | <0.001 |
| **Number of anti-HTN medication ingredients** | | | | | | |
| 0 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| 1 | 0.83 (0.77-0.90) | <0.001 | 0.83 (0.77-0.90) | <0.001 | 0.83 (0.78-0.90) | <0.001 |
| 2-3 | 0.81 (0.76-0.86) | <0.001 | 0.80 (0.75-0.85) | <0.001 | 0.80 (0.75-0.86) | <0.001 |
| >3 | 1.13 (1.05-1.21) | <0.001 | 1.07 (1.00-1.15) | 0.047 | 1.03 (0.96-1.10) | 0.38 |
| **Anti-HTN medication intensification score** | | | | | | |
| Quartile 1 | 1.00 (Ref.) | | 1.00 (Ref.) | | 1.00 (Ref.) | |
| Quartile 2 | 0.65 (0.61 - 0.69) | <0.001 | 0.68 (0.64, 0.73) | <0.001 | 0.68 (0.64 - 0.72) | <0.001 |
| Quartile 3 | 0.56 (0.53 - 0.59) | <0.001 | 0.61 (0.58, 0.65) | <0.001 | 0.62 (0.58 - 0.65) | <0.001 |
| Quartile 4 | 0.43 (0.40 - 0.46) | <0.001 | 0.47 (0.44, 0.51) | <0.001 | 0.47 (0.44 - 0.51) | <0.001 |

[a] Unadjusted models included each hypertension care delivery measure separately; [b] Model 1
adjusted for baseline systolic blood pressure; [c] Model 2 further adjusted for social vulnerability
index, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease,
atrial fibrillation, diabetes, and dementia.
Abbreviations: 95% CI, 95% confidence interval; BP, blood pressure; HTN, hypertension; OP,
outpatient visits; OR, odds ratio; SVI, social vulnerability index.
592

593 **Figure 1. Study design and time-aligned matching strategy.**

 **Figure 2. Association between hypertension care delivery measures and incident ischemic stroke stratified by baseline systolic**

597    **blood pressure.**

600    **Figure 3. Association between hypertension care delivery measures and incident ischemic stroke stratified by baseline systolic**

601    **blood pressure.**